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Abstract
Objective To evaluate the extent to which circulating biomarker and
supplements of vitamin D are associated with mortality from
cardiovascular, cancer, or other conditions, under various circumstances.
Design Systematic review and meta-analysis of observational studies
and randomised controlled trials.
Data sources Medline, Embase, Cochrane Library, and reference lists
of relevant studies to August 2013; correspondance with investigators.
Study selectionObservational cohort studies and randomised controlled
trials in adults, which reported associations between vitamin D (measured
as circulating 25-hydroxyvitamin D concentration or vitamin D supplement
given singly) and cause specific mortality outcomes.
Data extraction Data were extracted by two independent investigators,
and a consensus was reached with involvement of a third. Study specific
relative risks from 73 cohort studies (849 412 participants) and 22
randomised controlled trials (vitamin D given alone versus placebo or
no treatment; 30 716 participants) were meta-analysed using random
effects models and were grouped by study and population characteristics.
Results In the primary prevention observational studies, comparing
bottom versus top thirds of baseline circulating 25-hydroxyvitamin D
distribution, pooled relative risks were 1.35 (95% confidence interval
1.13 to 1.61) for death from cardiovascular disease, 1.14 (1.01 to 1.29)
for death from cancer, 1.30 (1.07 to 1.59) for non-vascular, non-cancer
death, and 1.35 (1.22 to 1.49) for all cause mortality. Subgroup analyses
in the observational studies indicated that risk of mortality was
significantly higher in studies with lower baseline use of vitamin D
supplements. In randomised controlled trials, relative risks for all cause
mortality were 0.89 (0.80 to 0.99) for vitamin D3 supplementation and
1.04 (0.97 to 1.11) for vitamin D2 supplementation. The effects observed
for vitamin D3 supplementation remained unchanged when grouped by
various characteristics. However, for vitamin D2 supplementation,
increased risks of mortality were observed in studies with lower
intervention doses and shorter average intervention periods.
Conclusions Evidence from observational studies indicates inverse
associations of circulating 25-hydroxyvitamin D with risks of death due
to cardiovascular disease, cancer, and other causes. Supplementation
with vitamin D3 significantly reduces overall mortality among older adults;
however, before any widespread supplementation, further investigations
will be required to establish the optimal dose and duration and whether
vitamin D3 and D2 have different effects on mortality risk.
Introduction
Vitamin D is a group of fat soluble vitamins responsible for
intestinal absorption of calcium and phosphate.1 Two major
forms of vitamin D exist. Vitamin D2 (ergocalciferol), found in
plants, is produced by ultraviolet B irradiation of ergosterol and
can be consumed as a supplement or in fortified foods.2Vitamin
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D3 (cholecalciferol), on the other hand, a product of ultraviolet
B irradiation of 7-dehydrocholesterol, is synthesised in the
human epidermis or consumed in the form of natural (for
example, fish) or fortified food sources or as a supplement.2
Supplementation with vitamin D has been shown to benefit
skeletal conditions such as rickets, fractures, and falls,3-5
although a similar effect on bonemineral density was not evident
in a recent review of trials.6 A growing body of evidence
indicates that vitamin D may reduce risks of a wide range of
diseases including multiple sclerosis, autoimmune disorders,
infections, and cardiometabolic and cancer outcomes,7-12
indicating a possible pleiotropic effect across extraskeletal
systems. However, the evidence for vitamin D reducing the risk
of non-skeletal diseases is still being debated.13
Suboptimal concentrations of vitamin D have also been
implicated as a potential determinant of mortality because of
its wide ranging anti-inflammatory and immune modulating
effects.2 14 15However, available observational studies examining
this intriguing link are yet to be rigorously reviewed, and the
extent to which vitamin D deficiency confers risk of death from
cardiovascular disease, cancer, or other conditions remains
uncertain. Although several individual reports and reviews have
been published on the topic,16-21 they vary greatly and lack
sufficient detail (for example, associations for diverse causes
of death or primary versus secondary prevention settings).
Additionally, interpretation of the earlier quantitative reviews
of randomised trials is difficult,18 21 as they typically include
studies with mixed interventions (for example, combined with
calcium intake, which has been associated with cardiovascular
risk22) and lack detailed assessments to distinguish the effects
across important characteristics (such as geographical location,
intervention dosage and duration, and follow-up time). A need
exists, therefore, for an adequately powered, comprehensive
assessment of associations of vitamin D concentrations with
the risk of mortality across primary and secondary prevention
settings and from a broad range of causes. This is of particular
importance because estimates of mortality risk remain a
cornerstone in formulating health policies to prevent or reduce
premature deaths and improve quality of life, and in this sense
vitamin D might play a key role.
In this study, we have aimed to summarise the available
observational and interventional evidence in one updated
systematic review and meta-analysis to (a) determine the
associations of 25-hydroxyvitamin concentrations with the risk
of cause specific mortality outcomes in observational cohort
studies; (b) quantify the effects of vitamin D supplementation
(overall and by subtypes), when given alone compared with
placebo or no treatment, on mortality outcomes in the
randomised controlled trials; and (c) examine all associations
under a wide range of study level characteristics.
Methods
Data sources, search strategy, and eligibility
criteria
We did this review according to a predefined protocol and in
accordance with the PRISMA and MOOSE guidelines
(eAppendix 1 and 2).23 24 Two independent authors, in
duplication, sought studies published before 1 August 2013
(date last searched) using Medline, Embase, and Cochrane
databases. The computer based searches combined terms related
to the exposure (such as vitamin D, 25-hydroxyvitamin D) and
outcomes (such as mortality, all cause mortality, death), without
any language restriction. Details of the search strategy are
provided in eAppendix 3. We sought studies that had reported
on associations of circulating vitamin D (measured as
25-hydroxyvitamin D) or vitamin D supplements with all cause
mortality (defined as deaths from any causes) or cause specific
mortality (defined as deaths due to cardiovascular disease,
cancer, and other causes), in which fatal outcomes were
registered according to the primary cause (or, in its absence, the
underlying cause), on the basis of coding from the international
classification of diseases or according to study defined
classifications; ascertainment was based on death certificates.
Study selection
Observational cohort studies were eligible for inclusion if they
assessed association of circulating 25-hydroxyvitamin D
concentration with cause specific or all cause deaths in adults,
and recruited participants from either of the following categories:
general populations—that is, participants not selected on the
basis of pre-existing chronic disease, including cardiovascular,
metabolic, malignant, or renal disorders (that is, primary
prevention cohorts); or people with pre-existing baseline
conditions mentioned above (that is, secondary prevention
cohorts). Intervention studies were eligible if they were
randomised; assessed effects of vitamin D supplements singly
(that is, randomised controlled trials with a “vitamin D alone”
intervention group) in adults compared with a placebo or no
treatment; and collected cause specific or all cause mortality
endpoints (as defined before). Two independent reviewers
worked together to screen the titles and abstracts of all initially
identified studies according to the selection criteria. Full texts
were retrieved for studies that satisfied all selection criteria. We
searched reference lists of selected studies and relevant
systematic reviews on the topic for additional publications.
Data extraction
Two independent authors extracted data, and a consensus was
reached with involvement of a third. We used a predesigned
data abstraction form to extract relevant information. This
included questions on study size, study design, baseline
population, location, age at baseline, duration of follow-up,
reported degree of adjustment (defined as “+” when relative
risks were adjusted for established cardiovascular risk factors
such as age, sex, smoking status, lipids, hypertension, history
of cardiometabolic disease; “++” when adjusted for other
potential risk factors such as physical activity, body mass index,
social status; and “+++” when additionally adjusted for other
additional variables such as bone minerals), type and numbers
of mortality outcomes, and reported relative risks. Where
appropriate, we extracted information on subtypes of vitamin
D supplement, number of participants in the supplement and
control groups, baseline circulating vitamin D concentration,
assay method, blinding status, and composition of supplement
or placebo. If risk estimates were unavailable from a published
report, we collected relevant data by corresponding with the
authors,25-27 abstracting from other published reviews,19 21 28 or
hand calculating on the basis of the available information from
the paper,29-31 where appropriate. Additionally, in the case of
multiple publications, we included the most up to date or
comprehensive information.32 33
Assessment of risk of bias
For observational cohort studies, we used the Newcastle-Ottawa
Scale to assess the risk of bias.34 This scale uses a star system
(with a maximum of nine stars) to evaluate a study in three
domains: selection of participants, comparability of study
groups, and the ascertainment of outcomes of interest. We
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judged studies that received a score of nine stars to be at low
risk of bias, studies that scored seven or eight stars to be at
medium risk, and those that scored six or less to be at high risk
of bias. Similarly, for the randomised trials, we used the
Cochrane Collaboration’s tool for assessing the risk of bias.35
This tool evaluates seven possible sources of bias: random
sequence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assessment,
incomplete outcome data, selective reporting, and other bias.
For each individual domain, we classified studies into low,
unclear, and high risk of bias.
Data synthesis and analysis
To enable a consistent approach to meta-analysis and
interpretation of findings in this review, we used previously
described methods to transform relative risk estimates for
association of circulating 25-hydroxyvitamin D and mortality
outcomes,36 which were often differently reported by each
observational cohort study (for example, per unit change, per
one standard deviation change, or comparing fifths, quarters,
thirds, and other groupings), to consistently correspond to
comparison of the bottom versus the top third of the baseline
distribution of 25-hydroxyvitamin D concentrations in each
study. Briefly, we transformed log risk ratios by assuming a
normal distribution, with the comparison between extreme thirds
being equivalent to 2.18 times the log risk ratio for one standard
deviation increase (or equivalently as 2.18/2.54 times the log
risk ratio for a comparison of extreme quarters). We calculated
standard errors of the log risk ratios by using published
confidence limits and standardised them in the same way. We
assumed hazard ratios and odds ratios to approximate the same
measure of risk ratios. We combined study specific risk ratios
by using a random effects model that included between study
heterogeneity (and additionally using fixed effect models).
Where studies reported risk ratios with varying degrees of
adjustments, we used the maximally adjusted estimate. We
based subsidiary assessments involving circulating
25-hydroxyvitamin D cut-offs (defined as 21-29, 10-20, and
<10 ng/mL)2 37 38 compared with the reference category (≥30
ng/mL) on combining comparable risk ratio estimates across
studies, using random effects meta-analyses (and additionally
using fixed effect models).39 40
For randomised intervention trials we used reported adjusted
risk ratios, or calculated study specific unadjusted risk ratios
based on event rates if these were unavailable, for overall
vitamin D supplementation (and individually by supplements
of vitamins D3 and D2 subtypes). We calculated summary risk
ratios by pooling the study specific estimates with a random
effects model that included between study heterogeneity (parallel
analyses used fixed effect models). We assessed consistency of
findings across studies with standard χ2 tests and the I2 statistic.41
We used random effects meta-regression to quantify
heterogeneity by comparing results from studies grouped
according to study level characteristics. Additionally, we did
univariate meta-regression analyses to investigate the effect of
study level characteristics such as daily intervention dose of
supplement and duration of intervention or follow-up on the
size of the effect estimates for both supplementation trials and
observational cohort studies. We used the natural logarithm of
the risk ratio as the dependent variable and the study level
characteristic as the explanatory factor. We assessed evidence
of publication bias by using funnel plots and the Egger test.42
We calculated the population attributable risk with the following
equation: PAR%=100×Pe(RR−1)/(Pe(RR–1)+1),43where Pe is
the prevalence of the exposure (eAppendix 5). All statistical
tests were two sided and used a significance level of P<0.05.
We used Stata release-12 for all statistical analyses.
Results
The search strategy identified 2704 unique citations. After initial
screening based on titles and abstracts, 320 articles remained
for further evaluation. Of these articles, 225 were excluded in
the subsequent detailed assessments for reasons shown in
eFigure 1. The remaining 95 unique study reports met our
inclusion criteria and were included in the meta-analysis
(eAppendix 6). In aggregate, these included studies comprised
880 128 unique participants and 71 625 mortality outcomes
(including 10 777 deaths from cardiovascular disease and 6911
deaths from cancer) (table⇓; eTables 1-3).
Association of circulating 25-hydroxyvitamin
D concentration with cause specific mortality
Circulating 25-hydroxyvitamin D concentration in relation to
subsequent risk of death was reported in 73 observational cohort
studies, involving 849 412 participants and 66 511 mortality
events recorded during an average follow-up ranging from 0.3
to 29 years (table⇓; eTable 1). Of these observational cohort
studies, 38 involved participants from Europe, 26 from North
America, 8 from the Asia-Pacific region, and 1 from South
America. The median age of all included participants was 63
(interquartile range 59-71) years. We judged eight studies to be
at low risk of bias, 41 to be at medium risk, and 24 studies to
be at high risk of bias (eTable 1). Of the medium quality studies,
all showed a potential bias in the selection of participants. The
median baseline concentration of 25-hydroxyvitamin D in these
studies was 20.7 (interquartile range 17.5-24.3) ng/mL. For the
primary prevention cohorts, pooled risk ratios in comparisons
of people in the bottom versus top thirds of the population
distribution of baseline circulating 25-hydroxyvitamin D
concentration, adjusted for several potential risk factors, were
1.35 (95% confidence interval 1.13 to 1.61) for death from
cardiovascular disease (6416 events), 1.14 (1.01 to 1.29) for
death from cancer (5003 events), 1.30 (1.07 to 1.59) for other
non-vascular, non-cancer death (1444 events), and 1.35 (1.22
to 1.49) for all cause mortality (48 488 events) (fig 1⇓ and
eFigure 2). The corresponding pooled risk ratios were broadly
similar in the secondary prevention cohorts. Additional analyses
by various cut-off values of circulating 25-hydroxyvitamin D
concentration showed a significant inverse association with all
cause mortality (P<0.05; fig 2⇓). Assuming linearity, each 10
ng/mL decline of 25-hydroxyvitamin D concentration was
associated with a 16% (95% confidence interval 8% to 23%)
increased risk of all cause mortality (fig 2⇓).
In subsidiary analyses, we found significant inverse associations
for various cause specific mortality outcomes, including deaths
due to coronary disease, lymphoma, upper digestive tract cancer,
and respiratory diseases (eFigure 3). We observed a moderate
level of heterogeneity in observational studies, which was only
partially explained by between study differences in various
subgroups (figures 3⇓, 4⇓, and 5⇓). Specifically, the risk of all
mortality outcomes for low baseline circulating
25-hydroxyvitamin D concentration was significantly higher in
studies in which less than 10% of the population used vitamin
D supplements (P for meta-regression<0.05; figures 3⇓, 4⇓, and
5⇓). Additionally, risk of all cause mortality in participants with
low 25-hydroxyvitamin D concentrations was significantly
higher in studies with less than five years’ average follow-up
(P for meta-regression=0.001; fig 5⇓). The overall associations
observed, however, were similar across other subgroups such
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as latitude of study location, sex, study quality, levels of
multivariate adjustment, assay methods, adjustments for
seasonality or socioeconomic status, and geographical location
(figures 3⇓, 4⇓, and 5⇓ and eFigure 4). Results from subsidiary
univariate meta-regression analyses showed no evidence of
associations of the duration of follow-up with risk of death from
cardiovascular disease, death from cancer, other non-vascular,
non-cancer death, and all cause mortality (P>0.05 for all)
(eFigure 5).
Effects of vitamin D supplementation on all
cause mortality
Twenty two randomised controlled trials reported effects of
vitamin D supplementation in isolation on mortality outcomes,
including a total of 30 716 participants in the supplement and
control groups combined (table⇓; eTable 3). Fourteen of these
trials assessed the effect of vitamin D3, and eight reported effects
of vitamin D2. Thirteen trials involved participants from Europe,
five fromNorth America, and four from the Asia-Pacific region.
The average age of participants included in these trials ranged
from 56 to 85 years. Eleven trials included participants from
community based registers (six from the general population and
five from care or residential homes), and the rest recruited
participants from clinical registers. The risk of bias assessment
in each trial is reported in eAppendix 4. Most of the trials had
a low risk of bias for random sequence generation, allocation
concealment, participants’ blinding, and selective reporting.
Seven trials had a high risk of bias for blinding of outcome
assessment, and eight had a high bias in outcome data
completion. Among the vitamin D3 studies, participants in the
intervention arm received vitamin D3 supplementation ranging
from 10 to 6000 IU/day, and oral tablets were the principle form
of supplementation. The corresponding range was 208 to 4500
IU/day for vitamin D2. After an average follow-up ranging from
0.38 to 6.8 years, a total of 2527 all cause mortality events
occurred among participants in the intervention group compared
with 2587 events in the control group, with a combined risk
ratio of 0.98 (0.94 to 1.02) in all studies. The corresponding
risk ratios according to type of vitamin D supplementation was
0.89 (0.80 to 0.99) for vitamin D3 and 1.04 (0.97 to 1.11) for
vitamin D2 (fig 6⇓).
We found no evidence of heterogeneity across vitamin D3
(eFigure 6a; P for heterogeneity=0.34) or vitamin D2 trials
(eFigure 6b; P for heterogeneity=0.38). For vitamin D3, the
overall effect did not vary significantly across location, sex,
population source, daily dose, and duration of intervention or
follow-up (P for metaregression>0.05; fig 7⇓). The effects,
however, differed importantly for vitamin D2 supplementation,
for which we observed an increased risk of mortality in the
randomised controlled trials that used an intervention dose of
600 to 2000 IU/day, had shorter average intervention period
(<1.5 v ≥1.5 years), and had high risk of bias (P for
metaregression≤0.05 for all; fig 7⇓). Similarly, results from
univariate meta-regression analysis showed no evidence of an
association of daily intervention dose or average intervention
period with treatment effect for vitamin D3 supplementation
(P=0.47 and 0.50, respectively). The evidence did, however,
suggest associations of daily intervention dose and average
intervention period with the treatment effect for vitamin D2
supplementation, although these were not statistically significant
(P=0.06 and 0.07, respectively) (eFigure 7).We had insufficient
data to meaningfully combine the effects of vitamin D
supplementation alone on cause specific mortality outcomes.
We found no evidence of publication bias across all included
studies in this review (P for Egger’s asymmetry>0.05 for all)
(eFigure 8).
Prevalence of vitamin D deficiency and
estimated absolute risk
In supplementary analyses, based on data from available cohorts,
the prevalence of vitamin D insufficiency (defined as
25-hydroxyvitamin D concentration <30 ng/mL) was 69.5%
(95% confidence interval 62.1% to 77.7%) for the United States
and 86.4% (78.4% to 95.2%) for Europe. Furthermore, using
25-hydroxyvitamin D concentrations less than 10 ng/mL as the
criterion, 4% and 15% of the general population were severely
deficient in the Europe and United States, respectively (eFigure
9). Additionally, using the most recent mortality statistics for
the United States and Europe,44 45 the estimated absolute risk
differences for all cause mortality associated with vitamin D
deficiency were 75.4 events in Europe and 96.6 events in the
United States, per 100 000 population, per year (eAppendix 5).
Using the population prevalence estimates of vitamin D
deficiency from this study, 9.4% of all deaths in Europe and
12.8% of those in the United States could be attributed to
vitamin D deficiency.
Discussion
The findings of this review indicate that a moderate, but
significant, inverse association exists between circulating
vitamin D concentrations and the risk of all cause mortality in
the primary prevention cohort studies. The inverse association
was evident generally for all broad causes of death and more
specifically for deaths due to coronary disease, lymphoma, upper
digestive cancer, and respiratory disorders. In all randomised
controlled trials combined, vitamin D supplementation, when
given alone, did not reduce overall mortality significantly among
older adults. However, when stratified by type of
supplementation, vitamin D3, given singly, reduced all cause
mortality significantly by 11%. By contrast, supplementation
with vitamin D2 alone had no overall effect on mortality.
Possible explanations for findings
The inverse association between vitamin D and mortality can
be explained by several different mechanisms. Firstly, activated
vitamin D may influence a range of biological responses
involved in cellular growth, proliferation, and apoptosis and
immune system functions.2 8 Vitamin D receptors and the
enzyme required for its activation are present in most human
cells and tissues, indicating a major role for vitamin D in
“non-skeletal” physiological processes. Secondly, approximately
3000 binding sites for the vitamin D receptor have been found
throughout the human genome,46 indicating regulation of a very
large number of genes (estimated to be about 3% of the human
genome2) either directly or indirectly responsive to vitamin D
receptors. This, along with the potential adverse consequences
of low 25-hydroxyvitamin D concentrations, such as coronary
heart disease, cancer, and death,47 found in people with
25-hydroxyvitamin D related genetic variants, reinforces the
importance of an endocrine system beyond extracellular calcium
and phosphate homeostasis.46 Thirdly, the positive association
between vitaminD concentrations and longer leucocyte telomere
length, a potential determinant of age related disorders and
overall longevity,48 emphasises the possible beneficial effects
of vitamin D on healthy ageing and associated outcomes.
Fourthly, as primary causes of vitamin D deficiency include
insufficient exposure to sunlight, poor diet, increased adiposity,
and reduced synthesis or absorption,49 a poor vitamin D status
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might essentially reflect suboptimal lifestyle and socioeconomic
circumstances. These individual level factors may, in turn,
influence risk for their potential roles on several established
determinants of morbidity andmortality such as smoking, blood
pressure, body mass index, and use of supplements.50 Although
most of the studies included in this review controlled for these
characteristics, and our pooled estimates were largely unchanged
when they were further stratified by adjustment for standard
socioeconomic factors, potential residual and unmeasured
confounding by differences in diet, lifestyle, and socioeconomic
status remains a concern. Such unaccounted confounding could
partly explain the discrepancy of findings observed earlier
between observational and interventional studies of other dietary
factors.51 Finally, our study indicates that vitamin D is inversely
and moderately associated with risk of death from coronary
disease, lymphoma, cancers of the upper digestive tract, and
respiratory disease. Although these associations require better
characterisation in future larger studies, local expression of
vitamin D receptors and systemic immunomodulatory roles of
vitamin D have been proposed to explain them.52-55
Subgroup analyses among observational studies indicated that
the inverse associations of circulating 25-hydroxyvitamin D
concentration with all cause and cancer specific mortality were
significantly stronger in the populations with a low prevalence
of vitamin D supplement use. This suggests that the effect of
vitamin Dmay be dependent on baseline vitamin D status. Given
that baseline circulating 25-hydroxyvitamin D concentrations
in a population with low prevalent vitamin D supplement use
is likely to be low,56 and that the risk of mortality outcomes is
known to be greater at the lower concentrations of
25-hydroxyvitamin D,27 these findings are not unexpected. In
addition, a previous study has suggested a threshold effect in
25-hydroxyvitamin D concentrations up to 112 nmol/L, which
can be achieved by daily use of 600 IU of vitamin D3.
57
Additionally, we found a significantly higher mortality risk of
low 25-hydroxyvitamin D concentrations in studies with a
follow-up of less than five years. This may be attributed to
reverse causality, in which people have underlying diseases that
are associated with low 25-hydroxyvitamin D concentrations,
such as cardiometabolic diseases.
Our meta-analysis of all available randomised controlled trials
of vitamin D supplements, given singly among principally older
adults, suggests that this nutrient may not significantly reduce
mortality outcomes. However, when we considered the effects
of specific vitamin D metabolites, supplementation in the form
of vitamin D3 (animal derived, known as cholecalciferol) but
not vitamin D2 (plant based, known as ergocalciferol) was
associated with reduced mortality. Earlier evidence described
ergocalciferol as being potentially less potent, unit for unit, in
maintaining 25-hydroxyvitamin D concentrations in the
circulation,58 so the expected effect of vitamin D3 on mortality
could be greater. Additionally, previous reviews reported that
in the absence of concomitant use of calcium supplements,
compared with vitamin D3, vitamin D2 was associated with a
significantly lower overall increase in serum 25-hydroxyvitamin
D concentration.59 60 Interestingly, concomitant use of vitamin
D with calcium at baseline was associated with lower increases
in 25-hydroxyvitamin D concentrations.59 Subgroup analyses
showed that vitamin D2 supplementation increased the aggregate
risk of mortality in trials that had shorter average intervention
periods. Similar higher risks were reported for trials using lower
intervention doses. The discrepant findings in our meta-analysis
could also be explained by insufficient power (average follow-up
duration in the vitamin D2 trials was about a year less than for
D3 trials) or, importantly, factors other than supplements
themselves in these studies (such as diversity in population
characteristics); therefore, further randomised controlled trials
are needed to reinforce these findings.
Comparison with previous work
Findings of this updated meta-analysis generally concur with
and further extend the previous reviews in several important
ways. Firstly, this study had enhanced power to examine the
associations in greater detail. For example, our meta-analysis
of the primary prevention cohort studies involved about 10 times
asmany participants and three times asmanymortality outcomes
as previous reviews on this topic combined,10 19 20 and included
about 10 recent, large scale observational cohort studies.
Secondly, in contrast to the earlier reviews, we have done a
systematic synthesis of all available primary and secondary
prevention cohorts to quantify the risk of both composite and
various cause specific death outcomes in a single comprehensive
investigation. Thirdly, we have analysed and presented
standardised pooled risk estimates comparing extreme thirds of
baseline distribution of vitamin D, and by pre-specified vitamin
D cut-offs. Fourthly, unlike previous reviews that included all
randomised studies with mixed interventions,18 21 our most up
to date meta-analysis of randomised controlled trials included
exclusively the studies that administered vitamin D alone.
Finally, we did detailed analyses under a broader range of
individual and study level circumstances to explore the potential
sources of heterogeneity. Nevertheless, the findings from our
trial component are consistent with the earlier meta-analysis
(based on randomised controlled trials irrespective of
concomitant supplementation with calcium) that also reported
heterogeneity in efficacy between the two forms of supplement.18
Implications of findings
Our findings may have several implications. They underscore
a potentially deleterious role of low vitamin D in all cause and
cause specific mortality in both primary and secondary
prevention cohorts. Additionally, a beneficial effect was
observed for supplementation with vitamin D3 in the randomised
controlled trials. This is of significant public health importance,
as the gradual decline in circulating 25-hydroxyvitamin D
concentrations reported globally is likely to continue owing to
the increase in the proportion of older populations, obesity, and
lack of adequate sun exposure combined with sunscreen use.61
Our review further highlights existing scientific gaps in the trial
evidence and, therefore, stimulates future research.62 For
instance, available intervention studies were generally
insufficiently powered to reliably assess the optimum dosage,
not able to examine potential toxic effects over prolonged use,
and unable to reliably assess the efficacy in low risk general
populations as most of the included community based studies
involved solely older participants. Finally, compared with other
conventional risk factors of ill health, the estimated population
attributable risk of death due to suboptimal vitamin D in our
study seems to be substantial. For example, in the United States,
we estimated the population attributable risk due to vitamin D
deficiency to be about 13%. The corresponding estimates in the
United States were about 20% for smoking,63 about 11% for
physical inactivity,64 and about 9% for alcohol consumption.65.
This reinforces the potential importance of scalable, cost
effective public health strategies (such as moderate sun
exposure, supplementation, and food fortification) in improving
the overall vitamin D status to reduce premature deaths
worldwide.
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Strengths and limitations of study
The generalisability of our findings has been enhanced by the
involvement of data from almost 900 000 participants in 26
nations. We used standardised estimates to allow consistent
comparisons and examined a wide range of characteristics.
However, the review was limited by the moderate amount of
available data on several cause specific mortality outcomes. For
example, even in aggregate, fewer than 1000 site specific cancer
deaths were generally recorded in the observational cohort
studies. Observational data also provide limited clarity on
whether observed associations with mortality outcomes are
direct (that is, due to suboptimal vitamin D) or indirect (due to
shared determinants such as obesity, body composition, or social
status). Furthermore, as all included observational studies lacked
serial assessment of circulating 25-hydroxyvitamin D
concentration in the same individuals, reliable assessment of
the extent of any within person variability in circulating
25-hydroxyvitamin D concentration was not possible. Because
most characteristics of epidemiological studies are measured
with a degree of error and are subject to fluctuations within
individuals over time, correction of such variability in future
studies would help to avoid “regression dilution.”66 67 Although
the observational studies are unable to assess the causal
association, evidence from the intervention studies could provide
concluding evidence in this respect. However, such trials are
generally sparse, include chiefly older people (that is, a
population with a high competing risk of death due to
comorbidities68), and do not typically present data on cause
specific deaths as the primary outcomes of interest. Furthermore,
although most of the trials included in this review seem to have
a low risk of bias, our findings should be interpreted with some
caution, owing to the relatively small number of trials for each
intervention subtype, especially for primary prevention.
Therefore, our findings intensify the need for detailed future
intervention studies that involve free living general populations,
quantify efficacy in important subgroups such as non-white
ethnicities, are adequately powered and sufficiently prolonged
to help judge appropriate dosage and safety, aim to ascertain a
broader range of fatal and non-fatal outcomes than has been
customary in the randomised controlled trials thus far, and study
both vitamin D2 and D3 to identify which form of vitamin D
supplementation can be most efficient and safe.
Conclusions
Evidence from observational studies indicates inverse
associations of circulating 25-hydroxyvitamin D concentration
with risks of death from cardiovascular disease, death from
cancer, and non-vascular, non-cancer death. Supplementation
with vitamin D3 reduced overall mortality significantly among
older adults; however, before any widespread supplementation,
further studies will be required to determine the optimal dose
and duration and to reliably establish whether vitamin D3 affects
the mortality risk differently than vitamin D2.
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Table
Table 1| Summary characteristics of included studies. Values are number of studies (number of participants) unless stated otherwise
Intervention studiesObservational cohort studies
Eligible studies
2273No of unique studies
1.4 (0.5-3.0)6.0 (3.0-9.5)Median (IQR) follow-up (years)
Participants
30 716849 412Total No of participants
343 (124-2578)1073 (510-2429)Median (IQR) No of participants
511466 511Total No of deaths
22.5 (7-471)224 (106-633)Median (IQR) No of deaths
—51 (35-62)Median (IQR) % male
77 (56-85)63 (59-71)Median (IQR) age (years)
Baseline population
9 (24 828)29 (788 282)Not selected on basis of prior chronic disease
13 (9195)44 (61 130)With pre-existing chronic disease
Location
13 (25 789)38 (330 573)Europe
5 (1939)26 (90 342)North America
4 (2988)8 (427 515)Asia-Pacific
—1 (982)South America
Sample type
—57 (822 340)Serum
—16 (27 072)Plasma
Assay method
—34 (61 013)Radioimmunoassay
—19 (753 285)Automated immunoassays
—20 (35 114)Chromatographic methods
25-hydroxyvitamin D concentration
15.2 (10.4-21.3)20.7 (17.5-24.3)Median (IQR) pooled concentration at baseline (ng/mL)
Outcome—No of studies (No of events)*
22 (5114)68 (64 636)All cause mortality
3 (574)29 (10 203)Cardiovascular mortality
2 (291)17 (6620)Cancer mortality
—10 (2565)Other non-vascular, non-cancer mortality
IQR=interquartile range.
*Several studies provided data on multiple outcomes of interest.
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Figures
Fig 1 Association of circulating 25-hydroxyvitamin D concentrations with cause specific mortality in observational cohort
studies. *Pooled estimates are based on random effects meta-analysis. Using fixed effects models, for primary prevention
cohorts, secondary prevention cohorts, and all cohorts, the estimates were 1.40 (1.32 to 1.47), 1.50 (1.35 to 1.66), and
1.42 (1.35 to 1.49) for cardiovascular deaths; 1.10 (1.02 to 1.17), 1.45 (1.28 to 1.65), and 1.16 (1.10 to 1.24) for cancer
deaths; 1.28 (1.12 to 1.47), 1.38 (1.09 to 1.75), and 1.30 (1.16 to 1.47) for non-vascular, non-cancer deaths; and 1.45 (1.41
to 1.49), 1.49 (1.42 to 1.56), and 1.44 (1.40 to 1.47) for all cause deaths. Size of data marker is proportional to inverse of
variance of relative risk; horizontal line represents 95%CI. Corresponding forest plots and I2 (95% CI) estimates are provided
in supplementary material
Fig 2 Association of circulating 25-hydroxyvitamin D concentrations with all cause mortality, based on primary prevention
cohorts. *Indirect comparisons based on available studies with relevant information in each category; summary estimates
presented were calculated using random effects models. Using fixed effects models, the estimates were 1.09 (1.06 to 1.11)
for clinical cut-off of 21-29 v ≥30, 1.20 (1.15 to 1.26) for 10-20 v ≥30, 1.23 (1.20 to 1.26) for <10 v ≥30, and 1.19 (1.18 to
1.21) per 10 ng/mL decrease
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Fig 3 Association of circulating 25-hydroxyvitamin D concentration and risk of cardiovascular disease mortality in primary
prevention cohorts, according to various characteristics. Based on available studies with relevant subgroup information.
CPBA=competitive binding protein assay; +=relative risks adjusted for established cardiovascular risk factors such as age,
sex, smoking status, lipids, hypertension, history of cardiometabolic disease; ++=adjusted for other potential risk factors
such as physical activity, body mass index, social status; +++=adjusted for other additional variables such as bone minerals.
*P<0.05 from meta-regression analyses. †Based on available studies with relevant subgroup information. ‡Based on
Newcastle-Ottawa scale.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g1903 doi: 10.1136/bmj.g1903 (Published 1 April 2014) Page 10 of 13
RESEARCH
Fig 4 Association of circulating 25-hydroxyvitamin D concentration and risk of cancer mortality in primary prevention cohorts,
according to various characteristics. Based on available studies with relevant subgroup information. CPBA=competitive
binding protein assay; +=relative risks adjusted for established cardiovascular risk factors such as age, sex, smoking status,
lipids, hypertension, history of cardiometabolic disease; ++=adjusted for other potential risk factors such as physical activity,
body mass index, social status; +++=adjusted for other additional variables such as bone minerals. *P<0.05 from
meta-regression analyses. †Based on available studies with relevant subgroup information. ‡Based on Newcastle-Ottawa
scale.
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Fig 5 Association of circulating 25-hydroxyvitamin D concentration and risk of all cause mortality in primary prevention
cohorts, according to various characteristics. Based on available studies with relevant subgroup information.
CPBA=competitive binding protein assay; +=relative risks adjusted for established cardiovascular risk factors such as age,
sex, smoking status, lipids, hypertension, history of cardiometabolic disease; ++=adjusted for other potential risk factors
such as physical activity, body mass index, social status; +++=adjusted for other additional variables such as bone minerals.
*P<0.05 from meta-regression analyses. †Based on available studies with relevant subgroup information. ‡Based on
Newcastle-Ottawa scale.
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Fig 6 Effects of vitamin D supplementation on all cause mortality when given alone, derived from available randomised
control trials. *Pooled estimates are based on random effects meta-analysis. Using fixed effects models, for community
dwelling, hospital based, and overall population, the estimates were 0.91 (0.81 to 1.01), 0.88 (0.77 to 1.01), and 0.90 (0.82
to 0.98) for vitamin D3 trials and 1.05 (0.94 to 1.17), 1.15 (0.63 to 2.11), and 1.03 (0.97 to 1.09) for vitamin D2 trials. Overall
fixed effect estimate for all trials was 0.98 (0.94 to 1.03). Size of data marker is proportional to inverse of variance of relative
risk; horizontal line represents 95% CI. Corresponding forest plots and I2 (95% CI) estimates are provided in supplementary
material
Fig 7 Effects of vitamin D supplementation on all cause mortality, derived from available randomised controlled trials and
according to various characteristics. Based on available studies with relevant subgroup information; P values are from
meta-regression analyses. *Low risk and high risk categories are defined by studies that met ≥5 criteria versus those that
met <5 criteria in Cochrane Collaboration’s tool, respectively
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